SG10201903142RA - Serpin fusion polypeptides and methods of use thereof - Google Patents
Serpin fusion polypeptides and methods of use thereofInfo
- Publication number
- SG10201903142RA SG10201903142RA SG10201903142RA SG10201903142RA SG10201903142RA SG 10201903142R A SG10201903142R A SG 10201903142RA SG 10201903142R A SG10201903142R A SG 10201903142RA SG 10201903142R A SG10201903142R A SG 10201903142RA SG 10201903142R A SG10201903142R A SG 10201903142RA
- Authority
- SG
- Singapore
- Prior art keywords
- polypeptide
- methods
- derived
- serpin
- molecules
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 12
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 12
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 12
- 102000008847 Serpin Human genes 0.000 title abstract 4
- 108050000761 Serpin Proteins 0.000 title abstract 4
- 239000003001 serine protease inhibitor Substances 0.000 title abstract 3
- 230000004927 fusion Effects 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 102000004127 Cytokines Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 102000007562 Serum Albumin Human genes 0.000 abstract 1
- 108010071390 Serum Albumin Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/524,832 US10400029B2 (en) | 2011-06-28 | 2014-10-27 | Serpin fusion polypeptides and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201903142RA true SG10201903142RA (en) | 2019-05-30 |
Family
ID=55858243
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201903142RA SG10201903142RA (en) | 2014-10-27 | 2015-10-27 | Serpin fusion polypeptides and methods of use thereof |
| SG11201703390SA SG11201703390SA (en) | 2014-10-27 | 2015-10-27 | Serpin fusion polypeptides and methods of use thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201703390SA SG11201703390SA (en) | 2014-10-27 | 2015-10-27 | Serpin fusion polypeptides and methods of use thereof |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP3212290A4 (ko) |
| JP (2) | JP6737781B2 (ko) |
| KR (2) | KR20170091096A (ko) |
| CN (2) | CN107206257A (ko) |
| AU (3) | AU2015339507B2 (ko) |
| BR (1) | BR112017008525A2 (ko) |
| CA (1) | CA2965151A1 (ko) |
| HK (1) | HK1244460A1 (ko) |
| IL (2) | IL308589A (ko) |
| MX (2) | MX2017005467A (ko) |
| RU (1) | RU2746550C2 (ko) |
| SG (2) | SG10201903142RA (ko) |
| UA (1) | UA127305C2 (ko) |
| WO (1) | WO2016069574A1 (ko) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021008200A2 (pt) * | 2018-10-29 | 2021-12-14 | Spin Therapeutics Llc | Composições e métodos para distúrbios de alfa-1-antitripsina |
| WO2020097946A1 (zh) * | 2018-11-18 | 2020-05-22 | 杭州博虎生物科技有限公司 | 一种重组人白细胞介素10融合蛋白及其应用 |
| CN112315897A (zh) * | 2020-11-04 | 2021-02-05 | 深圳前海鹰岗生物科技有限公司 | 一种抑制细胞炎症反应释放治疗痛风急性发作的聚合物微针及制备方法 |
| WO2022133521A1 (en) * | 2020-12-21 | 2022-06-30 | Macquarie University | Treatment of glaucoma |
| GB202102258D0 (en) * | 2021-02-17 | 2021-03-31 | Arecor Ltd | Novel composition |
| US20240139296A1 (en) * | 2021-03-03 | 2024-05-02 | Formycon Ag | Formulations of ace2 fc fusion proteins |
| CN113325181A (zh) * | 2021-04-25 | 2021-08-31 | 苏州市立医院(北区) | 丝氨酸蛋白酶抑制剂在用于脓毒症早期预警的标志物中的应用 |
| CN114874333A (zh) * | 2021-10-18 | 2022-08-09 | 深圳科兴药业有限公司 | 一种生长激素融合蛋白及其应用 |
| US20230364208A1 (en) | 2022-05-16 | 2023-11-16 | Inhibrx, Inc. | Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002537810A (ja) * | 1999-03-01 | 2002-11-12 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ヒトセルピンタンパク質 |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7217797B2 (en) * | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| UY28423A1 (es) * | 2003-07-18 | 2005-02-28 | Vertex Pharma | Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.- |
| EP3192872A1 (en) * | 2003-08-26 | 2017-07-19 | The Regents of the University of Colorado, a body corporate | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
| KR101027427B1 (ko) * | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | ＦcRn에 대하여 증가된 결합력을 갖는 Ｆc 변이체 |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| NZ565511A (en) * | 2005-07-22 | 2011-03-31 | Five Prime Therapeutics Inc | Compositions and methods of treating disease with FGFR fusion proteins |
| WO2007021807A1 (en) * | 2005-08-12 | 2007-02-22 | Schering Corporation | Mcp1 fusions |
| EP2671891A3 (en) * | 2008-06-27 | 2014-03-05 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| CN106432503B (zh) * | 2008-12-19 | 2020-03-06 | 宏观基因有限公司 | 共价双抗体及其用途 |
| PL2654780T3 (pl) * | 2010-12-23 | 2017-07-31 | Janssen Biotech, Inc | Aktywne mutanty przeciwciała fc odporne na proteazy |
| MX354359B (es) * | 2011-03-29 | 2018-02-28 | Roche Glycart Ag | Variantes de fragmento cristalizable (fc) de los anticuerpos. |
| EP2726092B1 (en) * | 2011-06-28 | 2019-06-19 | Inhibrx, LP | Serpin fusion polypeptides and methods of use thereof |
| KR20140068861A (ko) * | 2011-06-28 | 2014-06-09 | 인히브릭스 엘엘씨 | Wap 도메인 융합 폴리펩티드 및 이의 이용 방법 |
| CA2896951A1 (en) * | 2012-01-10 | 2013-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| CA2877363A1 (en) * | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function |
| BR112014028368A2 (pt) * | 2012-06-27 | 2017-11-14 | Hoffmann La Roche | método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica |
| EP2880170B1 (en) * | 2012-08-02 | 2016-08-24 | F. Hoffmann-La Roche AG | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF |
| US9758807B2 (en) * | 2012-12-05 | 2017-09-12 | SOLA Biosciences, LLC | Protein expression enhancing polypeptides |
-
2015
- 2015-10-27 KR KR1020177014414A patent/KR20170091096A/ko not_active IP Right Cessation
- 2015-10-27 RU RU2017118325A patent/RU2746550C2/ru active
- 2015-10-27 AU AU2015339507A patent/AU2015339507B2/en active Active
- 2015-10-27 CA CA2965151A patent/CA2965151A1/en active Pending
- 2015-10-27 EP EP15854670.5A patent/EP3212290A4/en active Pending
- 2015-10-27 JP JP2017522654A patent/JP6737781B2/ja active Active
- 2015-10-27 CN CN201580071331.7A patent/CN107206257A/zh active Pending
- 2015-10-27 KR KR1020237043666A patent/KR20240005109A/ko active Application Filing
- 2015-10-27 MX MX2017005467A patent/MX2017005467A/es unknown
- 2015-10-27 IL IL308589A patent/IL308589A/en unknown
- 2015-10-27 WO PCT/US2015/057533 patent/WO2016069574A1/en active Application Filing
- 2015-10-27 UA UAA201705128A patent/UA127305C2/uk unknown
- 2015-10-27 BR BR112017008525-9A patent/BR112017008525A2/pt active Search and Examination
- 2015-10-27 SG SG10201903142RA patent/SG10201903142RA/en unknown
- 2015-10-27 IL IL251799A patent/IL251799B2/en unknown
- 2015-10-27 CN CN202111439584.9A patent/CN114316068A/zh active Pending
- 2015-10-27 SG SG11201703390SA patent/SG11201703390SA/en unknown
-
2017
- 2017-04-26 MX MX2021012047A patent/MX2021012047A/es unknown
-
2018
- 2018-03-05 HK HK18103148.5A patent/HK1244460A1/zh unknown
-
2020
- 2020-07-16 JP JP2020121953A patent/JP2020180157A/ja active Pending
-
2021
- 2021-09-28 AU AU2021240153A patent/AU2021240153A1/en not_active Abandoned
-
2024
- 2024-05-29 AU AU2024203586A patent/AU2024203586A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3212290A1 (en) | 2017-09-06 |
| EP3212290A4 (en) | 2019-01-23 |
| RU2017118325A3 (ko) | 2019-03-21 |
| UA127305C2 (uk) | 2023-07-19 |
| AU2015339507A1 (en) | 2017-05-11 |
| MX2017005467A (es) | 2017-11-30 |
| BR112017008525A2 (pt) | 2018-01-30 |
| MX2021012047A (es) | 2021-11-03 |
| IL308589A (en) | 2024-01-01 |
| IL251799A0 (en) | 2017-06-29 |
| HK1244460A1 (zh) | 2018-08-10 |
| CN107206257A (zh) | 2017-09-26 |
| IL251799B2 (en) | 2024-04-01 |
| KR20240005109A (ko) | 2024-01-11 |
| SG11201703390SA (en) | 2017-05-30 |
| RU2017118325A (ru) | 2018-11-29 |
| AU2015339507B2 (en) | 2021-07-01 |
| JP6737781B2 (ja) | 2020-08-12 |
| KR20170091096A (ko) | 2017-08-08 |
| AU2024203586A1 (en) | 2024-06-20 |
| JP2017537888A (ja) | 2017-12-21 |
| IL251799B1 (en) | 2023-12-01 |
| RU2746550C2 (ru) | 2021-04-15 |
| WO2016069574A1 (en) | 2016-05-06 |
| AU2021240153A1 (en) | 2021-10-28 |
| JP2020180157A (ja) | 2020-11-05 |
| CN114316068A (zh) | 2022-04-12 |
| CA2965151A1 (en) | 2016-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021012047A (es) | Polipeptidos de fusion de serpina y metodos para utilizar los mismos. | |
| MX356517B (es) | Polipéptidos de fusión de serpina y métodos de uso de los mismos. | |
| MX2013015324A (es) | Polipeptidos de fusion con domino de proteína ácida del suero, y métodos de uso de los mismos. | |
| PH12020550205A1 (en) | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
| PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
| MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| MX2019003298A (es) | Proteinas de union recombinantes y sus usos. | |
| MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
| MX2021006017A (es) | Polipeptidos de folistatina y sus usos. | |
| EA201691669A1 (ru) | Связывающие сывороточный альбумин домены фибронектина iii типа | |
| AU2015269210A8 (en) | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof | |
| TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
| EA201791238A1 (ru) | Способы и композиции, в которых используются варианты полипептидов klotho | |
| MX2015000754A (es) | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. | |
| MX2021000155A (es) | Moleculas de proteina multifuncionales que comprenden decorina y su uso. | |
| PH12016501689B1 (en) | Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof | |
| WO2014144621A3 (en) | Modified fc fusion proteins | |
| MX2018003445A (es) | Expresion de proteinas que contienen fc. | |
| MX2015011931A (es) | Expresion mejorada de proteinas de picornavirus. | |
| MX2018013177A (es) | Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas. |